Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
REVB - Revelation Biosciences, Inc.
Market Cap 5.02M P/E 0.01 EPS this Y -2,047.20% Ern Qtrly Grth -
Income -15.9M Forward P/E -0.52 EPS next Y 51.10% 50D Avg Chg -13.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -79.00%
Dividend N/A Price/Book 0.39 EPS next 5Y - 52W High Chg -96.00%
Recommedations 2.00 Quick Ratio 1.09 Shares Outstanding 3.76M 52W Low Chg 15.00%
Insider Own 0.14% ROA -42.07% Shares Float 1.64M Beta 0.19
Inst Own 1.35% ROE -253.32% Shares Shorted/Prior 25.65K/313.73K Price 0.83
Gross Margin - Profit Margin - Avg. Volume 232,706 Target Price 14.45
Oper. Margin - Earnings Date Nov 7 Volume 105,693 Change -1.16%
Healthcare | Biotechnology | United States
About Revelation Biosciences, Inc.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Revelation Biosciences, Inc. News
12/03/24 Sector Update: Health Care Stocks Mixed Late Afternoon
12/03/24 Top Midday Decliners
12/03/24 Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
12/02/24 REVB Gets FDA Go Ahead
12/02/24 Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
11/12/24 Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
11/11/24 REVB Results Set Stage for Future Growth
11/08/24 Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
09/24/24 Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
04:30 PM Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
08/12/24 REVB: Bolsters Cash Amid Positive Trial Results
08/09/24 Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
07/08/24 REVB Releases Positive Test Results—Potential Catalyst
06/24/24 Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
06/24/24 Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
06/13/24 Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
05/13/24 REVB: In Great Position For Testing
05/10/24 Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
03/25/24 REVB Begins Trials with Good Cash on Hand
03/22/24 Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TIDMARSH GEORGE F Director Director Oct 16 Sell 0.6501 1,845 1,199 27,771 10/18/23
TIDMARSH GEORGE F Director Director Sep 28 Sell 0.69 1,429 986 42,096 10/02/23
TIDMARSH GEORGE F Director Director Sep 14 Sell 0.74 25,500 18,870 39,348 09/18/23
TIDMARSH GEORGE F Director Director Feb 25 Buy 1.60 20,000 32,000 467,156 02/28/22
TIDMARSH GEORGE F Director Director Feb 08 Buy 2.55 31,000 79,050 447,156 02/10/22
TIDMARSH GEORGE F Director Director Feb 04 Buy 2.46 50,000 123,000 1,523,335 02/08/22